The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, which ranks as the sixth of cancer-related death. Despite the emergence of targeted therapy, advanced-stage HCC remains largely incurable due to low response rate and therapeutic resistance. In this review, we mainly focused on the current progression of multi-kinase inhibitors and immunotherapies in the treatment of HCC. We highlight the mechanism underlying the ineffectiveness of these targeted therapies, including oncogenic alterations in driver genes and downstream pathways, high heterogeneity of HCC, and the mutual interaction of tumor microenvironment that promotes therapeutic resistance. We also discussed how these previous studies suggested for future therapeutic strategies. Besides, the complexity of HCC heterogeneity and cancer revolution need to be recognized in personalized therapy. Establishment of a drug screening system and identification of biomarkers of response is also in urgent need to overcome drug resistance. Meanwhile, a combination of targeted therapies could also be explored as a promising strategy in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Chen, C.-L., Uthaya Kumar, D. B., Punj, V., Xu, J., Sher, L., Tahara, S. M., Hess, S., & Machida, K. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.004 · Cited by 388
RetractedReciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells
Chen, C.-L., Tsukamoto, H., Liu, J.-C., Kashiwabara, C., Feldman, D., Sher, L., Dooley, S., French, S. W., Mishra, L., Petrovic, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65859 · Cited by 162
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33326-3 · Cited by 6,145
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
Demetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355
Understanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
Hernandez–Gea, V., Toffanin, S., Friedman, S. L., & Llovet, J. M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.002 · Cited by 722
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 710
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Zhu, Y.-J., Zheng, B., Wang, H.-Y., & Chen, L. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.5 · Cited by 702
Self-citationCainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Zhu, A. X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H. Y., Poon, R. T. P., Blanc, J.-F., Vogel, A., Chen, C.-L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.034 · Cited by 552
Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., & Asada, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5270 · Cited by 530
Yamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research · doi:10.1155/2014/638747 · Cited by 475
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Tumor Microenvironment and Differential Responses to Therapy
Hirata, E., & Sahai, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026781 · Cited by 422
Rimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Porta, C., Daniele, B., Bolondi, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30146-3 · Cited by 351
Heterogeneity of liver cancer and personalized therapy
Li, L., & Wang, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.07.018 · Cited by 339
Self-citationPhase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Ikeda, K., Kudo, M., Kawazoe, S., Osaki, Y., Ikeda, M., Okusaka, T., Tamai, T., Suzuki, T., Hisai, T., Hayato, S., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-016-1263-4 · Cited by 338
Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M., Higashiyama, S., Noda, K., Miyoshi, E., Monden, M., & Matsuura, N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1580 · Cited by 321
Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., Kong, J., Wang, H., Yang, S., Gu, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1170 · Cited by 313
Self-citationLachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306
Sawada, Y., Yoshikawa, T., Nobuoka, D., Shirakawa, H., Kuronuma, T., Motomura, Y., Mizuno, S., Ishii, H., Nakachi, K., Konishi, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3044 · Cited by 302
Precision diagnosis and treatment of liver cancer in China
Fu, J., & Wang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.10.008 · Cited by 301
Self-citationShan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., et al. (2012) · Hepatology · doi:10.1002/hep.25745 · Cited by 296
Liang, Y., Zheng, T., Song, R., Wang, J., Yin, D., Wang, L., Liu, H., Tian, L., Fang, X., Meng, X., et al. (2013) · Hepatology · doi:10.1002/hep.26224 · Cited by 289
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., Hohmeyer, A., Pesic, M., Leibold, J., von Thun, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3679 · Cited by 282
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Delire, B., & Stärkel, P. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12441 · Cited by 275
Wu, Q., Zhou, W., Yin, S., Zhou, Y., Chen, T., Qian, J., Su, R., Hong, L., Lu, H., Zhang, F., et al. (2019) · Hepatology · doi:10.1002/hep.30593 · Cited by 269
Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., Zhou, S., Liang, Y., Huang, D., Liang, X., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.019 · Cited by 251
EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation
Lanaya, H., Natarajan, A., Komposch, K., Li, L., Amberg, N., Chen, L., Wculek, S. K., Hammer, M., Zenz, R., Peck-Radosavljevic, M., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3031 · Cited by 242
Self-citationWu, F.-Q., Fang, T., Yu, L.-X., Lv, G.-S., Lv, H.-W., Liang, D., Li, T., Wang, C.-Z., Tan, Y.-X., Ding, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.019 · Cited by 241
Self-citationPavlakis, N., Sjoquist, K. M., Martin, A. J., Tsobanis, E., Yip, S., Kang, Y.-K., Bang, Y.-J., Alcindor, T., O’Callaghan, C. J., Burnell, M. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.1901 · Cited by 232
Zheng, L., Yang, W., Wu, F., Wang, C., Yu, L., Tang, L., Qiu, B., Li, Y., Guo, L., Wu, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0203 · Cited by 221
Self-citationGenomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy
Dhanasekaran, R., Nault, J.-C., Roberts, L. R., & Zucman-Rossi, J. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.11.001 · Cited by 208
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Teufel, M., Seidel, H., Köchert, K., Meinhardt, G., Finn, R. S., Llovet, J. M., & Bruix, J. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.261 · Cited by 202
On the cytokines produced by human neutrophils in tumors
Tecchio, C., Scapini, P., Pizzolo, G., & Cassatella, M. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.004 · Cited by 188
Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0782 · Cited by 185
Feng, M., Gao, W., Wang, R., Chen, W., Man, Y.-G., Figg, W. D., Wang, X. W., Dimitrov, D. S., & Ho, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217868110 · Cited by 183
Biological Roles and Mechanisms of Circular RNA in Human Cancers
Tang, Q., & Hann, S. S. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s233672 · Cited by 170
Targets for immunotherapy of liver cancer
Greten, T. F., & Sangro, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.007 · Cited by 168
Buckley, A. F., Burgart, L. J., Sahai, V., & Kakar, S. (2008) · American Journal of Clinical Pathology · doi:10.1309/wf10qaaed3pp93bh · Cited by 165
Gao, W., Tang, Z., Zhang, Y., Feng, M., Qian, M., Dimitrov, D. S., & Ho, M. (2015) · Nature Communications · doi:10.1038/ncomms7536 · Cited by 155
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients
Han, T., Xiang, D., Sun, W. C., Liu, N., Sun, H., Wen, W., Shen, W.-F., Wang, R., Chen, C. Y., Wang, X., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.036 · Cited by 150
Self-citationZhao, D., Zhai, B., He, C., Tan, G., Jiang, X. L., Pan, S., Dong, X., Wei, Z., Ma, L., Qiao, H., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.01.026 · Cited by 150
Xiang, D., Cheng, Z., Liu, H., Wang, X., Han, T., Sun, W. C., Li, X., Yang, W., Chen, C. Y., Xia, M., et al. (2016) · Hepatology · doi:10.1002/hep.28919 · Cited by 150
Self-citationKohga, K., Takehara, T., Tatsumi, T., Ishida, H., Miyagi, T., Hosui, A., & Hayashi, N. (2009) · Hepatology · doi:10.1002/hep.23456 · Cited by 149
Fang, J., Xu, L., Shang, L., Pan, C., Ding, J., Tang, Y., Liu, H., Liu, C.-X., Zheng, J., Zhang, Y., et al. (2018) · Hepatology · doi:10.1002/hep.30366 · Cited by 146
Martinez-Quetglas, I., Pinyol, R., Dauch, D., Torrecilla, S., Tovar, V., Moeini, A., Alsinet, C., Portela, A., Rodríguez‐Carunchio, L., Solé, M., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.001 · Cited by 143
Liu, L., Ho, R. L. K., Chen, G. G., & Lai, P. B. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0552 · Cited by 140
Abou-Alfa, G. K., Puig, O., Daniele, B., Kudo, M., Merle, P., Park, J.-W., Ross, P., Peron, J.-M., Ebert, O., Chan, S., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.004 · Cited by 137
Li, X., Chen, C. Y., Xiang, D., Qu, L., Sun, W. C., Lu, X., Zhou, T., Chen, S., Ning, B., Cheng, Z., et al. (2017) · Hepatology · doi:10.1002/hep.29372 · Cited by 127
Self-citationOncogenic driver genes and tumor microenvironment determine the type of liver cancer
Wang, G., Wang, Q., Liang, N. N., Xue, H., Yang, T., Chen, X., Qiu, Z., Zeng, C., Sun, T., Yuan, W., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2509-x · Cited by 111
Thabut, D., Routray, C., Lomberk, G. A., Shergill, U., Glaser, K. J., Huebert, R. C., Patel, L. S., Masyuk, T. V., Blechacz, B. R. A., Vercnocke, A. J., et al. (2011) · Hepatology · doi:10.1002/hep.24427 · Cited by 107
Kang, Y., Yau, T. C. C., Park, J.-W., Lim, H. Y., Lee, T.-H., Obi, S., Chan, S. L., Qin, S., Kim, R. D., Casey, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv388 · Cited by 106
Dietrich, P., Koch, A., FRITZ, V. K., Hartmann, A., Bosserhoff, A., & Hellerbrand, C. (2017) · Gut · doi:10.1136/gutjnl-2017-315402 · Cited by 102
Chen, C., Li, K., Jiang, H., Song, F., Gao, H., Pan, X., Shi, B., Bi, Y., Wang, H., Wang, H., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1949-8 · Cited by 100
Self-citationLing, S., Song, L., Fan, N., Feng, T., Liu, L., Yang, X., Wang, M., Li, Y., Tian, Y., Zhao, F. H., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3799 · Cited by 95
Lin, X., Hu, L., Gu, J., Wang, R., Li, L., Tang, J. P., Zhang, B., Yan, X., Zhu, Y., Hu, C., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.033 · Cited by 80
Self-citationSorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
Gao, J., Shi, Z.-Y., Xia, J.-F., Inagaki, Y., & Tang, W. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i42.12059 · Cited by 75
Pan, Z., Di, S., Shi, B., Jiang, H., Shi, Z., Liu, Y., Wang, Y., Luo, H., Yu, M., Wu, X., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2221-1 · Cited by 63
Chakraborty, S., Dlie, Z. Y., Chakraborty, S., Roy, S., Mukherjee, B., Besra, S. E., Dewanjee, S., Mukherjee, A., Ojha, P. K., Kumar, V., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.01.034 · Cited by 59
Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
Kim, B. H., Park, J., Kim, J. S., Lee, S.-K., & Hong, E. K. (2019) · Gut and Liver · doi:10.5009/gnl18345 · Cited by 49
Long non-coding RNA THOR promotes liver cancer stem cells expansion via β-catenin pathway
Cheng, Z., Lei, Z., Yang, P., Si, A., Xiang, D., Zhou, J., & Hüser, N. (2018) · Gene · doi:10.1016/j.gene.2018.10.051 · Cited by 45
Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity
Liu, Q., Wen, W., Tang, L., Qin, C., Lin, Y., Zhang, H., Wu, H., Ashton, C., Wu, H., Ding, J., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1183850 · Cited by 41
Self-citationSun, D., Liu, H., Dai, X., Zheng, X., Yan, J., Wei, R., Fu, X., Huang, M., Shen, A., Huang, X., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.029 · Cited by 39
lncARSR promotes liver cancer stem cells expansion via STAT3 pathway
Yang, C. Z., Cai, W., Dong, Z., Guo, J.-W., Zhao, Y., Sui, C., & Yang, J. (2018) · Gene · doi:10.1016/j.gene.2018.10.087 · Cited by 37
Treating advanced hepatocellular carcinoma: How to get out of first gear
Harding, J. J., & Abou‐Alfa, G. K. (2014) · Cancer · doi:10.1002/cncr.28850 · Cited by 34
Ke, S., Chen, S., Dong, Z., Hong, C. S., Zhang, Q., Tang, L., Yang, P., Zhai, J., Yan, H., Shen, F., et al. (2016) · Hepatology · doi:10.1002/hep.28889 · Cited by 29
Self-citation
Cited by
Mechanisms of drug resistance in HCC
Ladd, A. D., Duarte, S., Sahin, I., & Zarrinpar, A. (2024) · Hepatology · doi:10.1097/hep.0000000000000237 · Cited by 363
Metadata
- Authors
- Chen, S., Cao, Q., Wen, W., & Wang, H.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 460
- Pages
- 1-9
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2949512677
- Cited by
- 255
- References
- 105
- FWCI
- 18.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.